Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr. Steven Lydeamore, will present today at the ASX Small and Mid-Cap Conference 2020, a virtual conference.
Drugs & OTC
Steven Lydeamore, Chief Executive Officer, Anatara Lifesciences (ASX:ANR) will be presenting at the ASX Small and Mid-Cap Conference 2020.
Anatara Lifesciences (ASX:ANR) today released its Appendix 4E and review of operations for the period ending 30 June 2020.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide an update on initiation of challenge study in poultry with the recently developed bromelain-based formulation (ANR-pf).
Cann Global continued to drive sales throughout the quarter resulting in cash receipts from customers of $333k up 54.6% on the prior corresponding period, but lower than the prior quarter due to shipping delays and therefore delayed payment on contracted sales.
While focussing financial resources on development of GaRP, Anatara has been evaluating development, in collaboration with third parties, additional dosage forms for piglets and to utilise Anatara's intellectual property in other species including in-feed formulations for piglets, formulations for aquaculture and formulations for poultry.
Cann Global Limited (ASX:CGB) is pleased to confirm that the 1 for 4 renounceable entitlement offer announced on 3 July 2020 (Entitlement Offer), closed on Thursday 23 July 2020.
Banking & Finance
- iSignthis Ltd (ASX:ISX) Damages Claim Increases by $200.7m to Over $464.7m
- Anatara Lifesciences (ASX:ANR) ASX Small and Mid-Cap Conference 2020
- Rofina Group Limited (NSX:218) IPO on the National Stock Exchange of Australia
Oil Gas & Energy
- State Gas Limited (ASX:GAS) New Record Gas Flow at Reids Dome Project
- Vintage Energy Ltd (ASX:VEN) Vali Gas Field Development Concept Completed
- Vintage Energy Ltd (ASX:VEN) Institutional Placement and Entitlement Offer